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A B S T R A C T   
When used for the evaluation of drug efficacy against Psoroptes ovis, the diagnostic performance of different 
sampling strategies for a mite count reduction test (MCRT) remains unclear. In the present study, a novel 
simulation framework was constructed that accounted for relevant biological features of P. ovis infestations in 
cattle and that was parameterized with field data from 16 farms (154 animals). Second, this framework was 
applied to explore the impact of study specific factors (number of animals, number of sampled lesions, and 
number of scrapings per lesion) and biological factors (mite infestation intensity and size of lesions) on the 
diagnostic performance of MCRT. Its outcome provided a basis to determine the diagnostic performance of MCRT 
when it was applied according to the World Association for the Advancement in Veterinary Parasitology 
(WAAVP) and the European Medicine Agency (EMA) guidelines, and to formulate recommendations to ensure a 
good diagnostic performance of the MCRT. For both guidelines, the MCRT allowed to correctly detect (power 
80%) reduced and normal efficacy when the therapeutic efficacy was <70%, and ≥95%, respectively. The results 
highlighted a reliable diagnostic performance of the MCRT when performed as recommended by WAAVP and 
EMA for the detection of normal drug efficacy. When used for the detection of reduced efficacy, therapeutic 
efficacies between 70% and 90% could not be detected with sufficient reliability. The diagnostic performance can 
be improved by increasing the total number of skin scrapings (increasing the number of animals, number of 
sampled lesions and/or number of samples per lesion). In order to help researchers and veterinarians to optimize 
the design of the MCRT to their field settings, the findings were translated into a simple tool.   
1. Introduction 
The mite Psoroptes ovis causes an exudative dermatitis in beef cattle 
and sheep, predominantly localized on the back of the animal. When left 
untreated, lesions can generalize and even result in death of the animal 
(Kirkwood, 1986; Losson et al., 1999; Bridi et al., 2001; Van Den Broek 
and Huntley, 2003; Fischer and Walton, 2014). The resulting financial 
losses and decline in animal welfare can be substantial, due to reduced 
growth and leather quality (Lonneux et al., 1998; Rehbein et al., 2003, 
2016). In cattle, the disease is geographically limited to Europe and 
certain parts of North and South America (Sarre et al., 2012), whereas in 
sheep, psoroptic mange is endemic in Europe, Africa, North and South 
America (ADAS, 2008). 
Acaricides are at the centre of mange treatment, with the macrocy-
clic lactones, pyrethroids, amitraz and phoxim as possible active com-
pounds. However, due to the development of resistance, the therapeutic 
efficacy can be reduced. This can lead to treatment failure and 
consequently important animal welfare issues and more financial losses 
due to additional treatment costs and continuing production losses. At 
the time of writing, resistance in P. ovis in cattle has only been reported 
for the macrocyclic lactones (Lonneux et al., 1998; Genchi et al., 2008; 
Lekimme et al., 2010; Sarre et al., 2015; Lifschitz et al., 2018; van Mol 
et al., 2020). 
The reduction in mite counts following drug administration (mite 
count reduction test; MCRT) is used to measure the therapeutic efficacy 
of acaricides, and guidelines on how to best design the MCRT are pro-
vided by the World Association for the Advancement of Veterinary 
Parasitology (WAAVP) and the European Medicines Agency (EMA) 
(Committee for medicinal products for veterinary use(CVMP), 2005; 
Vercruysse et al., 2006). Unfortunately, both guidelines provide quite 
different recommendations. For example, they both agree on mite count 
reduction of at least 90% to define a normal drug efficacy, but they differ 
in number of animals (6 vs. 15), number of skin scrapings per animal (≥6 
if large lesions or ≥2 if small lesions vs. 3 without any specification of the 
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size of lesions), size of the sampled skin surface (3 cm × 3 cm vs. no 
recommendations) and number of lesions sampled (no recommenda-
tions vs. 3). 
There is little compliance to these guidelines, as shown by the di-
versity in sampling strategies applied to assess drug efficacy under field 
conditions (number of animals included: 6 to 15; number of skin 
scrapings per animal: 1 to 6; surface of scraping: 4 cm2– 9 cm2; Lonneux 
and Losson, 1992; Lonneux et al., 1997; Bridi et al., 2001; Rehbein et al., 
2002; Committee for medicinal products for veterinary use(CVMP), 
2005; Vercruysse et al., 2006; Genchi et al., 2008; Lekimme et al., 2010; 
Hamel et al., 2014; Sarre et al., 2015; Lifschitz et al., 2018; van Mol 
et al., 2020). This lack in standardisation jeopardises a direct compari-
son of results across studies and a reliable assessment of acaricide 
resistance. 
More generally, it is not clear how these different study specific 
factors affect the final conclusions, and this lack of insights hampers any 
evidence-based guidance on how to optimize the diagnostic accuracy of 
MCRT to correctly detect normal and reduced efficacy. Confronted with 
a similar challenge to detect reduced efficacy against gastrointestinal 
nematodes by means of a faecal egg count reduction test (FECRT), re-
searchers recently performed a series of simulation studies that were 
designed to assess the impact of both study specific factors (the number 
of animals and the sensitivity of the diagnostic method used) and bio-
logical factors (the intensity and distribution of infections among the 
animals) on the diagnostic accuracy of FECRT (Levecke et al., 2012, 
2018). Overall, these studies confirmed that the diagnostic accuracy of 
FECRT is affected by a complex interplay of the aforementioned factors, 
and that the diagnostic value of FECRT to detect anthelmintic resistance 
early is limited. 
Although such a simulation study is also primordial to formulate 
more evidence-based recommendations for MCRT, such a simulation 
framework that accounts for all the biological features of mite in-
festations in cattle is lacking. The only simulation studies performed for 
P. ovis were a Leslie-matrix simulation to study the population growth in 
sheep under favourable conditions and a model to simulate the patho-
genicity of biological agents for the control of P. ovis (Wall et al., 1999; 
Rose and Wall, 2009). This lack of P. ovis simulations is mainly because 
there are little insights on the biological distribution of mite counts at 
the level of farms, individual animals and skin surfaces (with and 
without lesions), yet these are of utmost importance to reliably mimic 
field conditions. For example, Sarre et al. (2015) and van Mol et al. 
(2020) reported details on the distribution of mite counts, reporting 
both mean and range of mite counts across farms, whereas others 
divided their mite counts in different arbitrary categories (Lonneux and 
Losson, 1992; Genchi et al., 2008; Lekimme et al., 2010; Lifschitz et al., 
2018). P. ovis mites are distributed throughout the entire lesion and not 
restricted to the periphery of the lesion, as is the case in sheep (Losson 
et al., 1999), but a more detailed description of the distribution within 
lesions is still lacking. 
In contrast to FECRT, where counting eggs in stool does not affect the 
worm burden, skin scrapings imply removal of the mites. Hence, taking 
skin scrapings prior to drug administration may already induce a sig-
nificant reduction in mite counts at follow-up, which may potentially 
hide an underlying reduced therapeutic efficacy. 
The overall aim of the present study was to develop recommenda-
tions for surveys on acaricide resistance in P. ovis. To this end, a simu-
lation framework was first constructed that accounts for the most 
important biological features of P. ovis infestations. Second, this 
framework was applied to explore the impact of both study specific 
factors (number of animals, number of sampled lesions and number of 
scrapings per lesion) and biological factors (intensity of mite infestation 
and size of lesions) on the diagnostic performance of MCRT. Based on 
the outcome of the simulation study, the diagnostic performance of 
MCRT was determined when it is applied according to the existing 
WAAVP and EMA guidelines, and recommendations were formulated to 
ensure a good diagnostic performance of the MCRT. Finally, a simple 
supporting tool was developed that will help researchers and veteri-
narians to further optimize the design of the MCRT to their own field 
settings. 
2. Material and methods 
2.1. Construction of a simulation framework for MCRT accounting for the 
biological features of psoroptic mange 
To mimic the field condition as much as possible, a simulation 
framework was constructed that accounts for both the variation in mite 
counts at different levels (Level 1: farm, Level 2: animal and Level 3: 
lesion), the difference in mite counts across lesions and non-lesions, the 
variation in size of lesions, and the removal of mites by taking skin 
scrapings. The parameterisation of these variables was based on re- 
analyses of field data (van Mol et al., 2020) and collection of new 
field data. 
Subsequently, the MCRT was mimicked in an iterative process, 
during which it was verified whether the MCRT allowed for a correct 
classification of the true underlying drug efficacy (TDE) under varying 
scenarios for both infestation intensities (mean mite counts at farm 
level) and sampling strategy (number of animals, number of sampled 
lesions, surface of lesion and number of scrapings per lesion). 
All simulations and statistical analyses were performed in R (R Core 
Team, 2018). The script for the simulation framework can be found in 
Supplementary Info I1. 
2.1.1. General simulation framework 
A representation of the general simulation framework is shown in 
Fig. 1. Each iteration starts with virtually counting the mite counts in 
skin scrapings of 3 cm by 3 cm from lesions prior to drug administration. 
To this end, a farm f was defined (Level 1), where the mean and variance 
in mite counts across individuals equalled μf and σ2f, respectively. In 
order to get to the level of individual animal a (Level 2), a subset of na 
non-zero mite counts were randomly selected within this virtual farm 
and assigned to na animals, each mite count corresponding to the mean 
mite counts/9 cm2 for each individual animal a (μfa). These mite counts 
were drawn either from a negative binomial distribution with mean μf 
and an aggregation kf (= μf2/(σ2f - μf)) in case of kf > 0 or from a Poisson 
distribution (λf = μf) in case of kf ≤ 0. 
For each animal a, the variation in mite counts (σ2fa) was then 
defined as a function of μfa and a random subset of 1000 mite counts was 
drawn from either a negative binomial distribution (kfa >0) or a Poisson 
distribution (kfa ≤0). Then, these mite counts were grouped into 5 strata 
based on the quintiles, each stratum representing a level of mite infes-
tation. In order to get the distribution on the level of individual lesion l 
(Level 3), a random subset of nl mite counts was proportionally selected 
across the different strata applying a multinomial distribution with 
probabilities π1 - π5 to select mite counts in strata 1 to 5, respectively. 
This methodology allowed to differentiate skin areas with more mite 
counts (lesions) from those with lower mite counts (healthy skin areas). 
Each of these mite counts was assigned to nl lesions within an animal a, 
and they corresponded to the mean mite counts/9 cm2 within these le-
sions (μfal). 
For each lesion l, the variation in mite counts within each lesion 
(σ2fal) was then defined as a function of μfal, and a random subset of ntot 
mite counts was drawn from either a negative binomial distribution (kfal 
>0) or a Poisson distribution (kfal ≤0). These mite counts corresponded 
with the ntot skin areas of 9 cm2 that can be scraped within a lesion with a 
surface Sfal. For example, in a Sfal of 180 cm2 the ntot equals 20 (= 180 
cm2/9 cm2). Finally, a predetermined subset of ns scrapings was 
randomly selected from these ntot mite counts, resulting in na x nl x ns pre- 
drug administration mite counts across na animals of farm f. 
In a second step, the post-drug administration mite counts were 
defined when a drug d with efficacy of TDEd is administered to all na 
animals. For the mite counts following drug administration, it was 
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assumed that skin scrapings are taken from the same lesions, but that the 
skin area sampled within a lesion l could be different. This implies that 
there is already a reduction in mite counts solely due to the removal of 
mites prior to the drug administration. To account for this, the mite 
counts for each 9 cm2 within each lesion l of animal a were first 
generated by multiplying these counts by 1 – TDEd. Subsequently, the 
mite counts of skin areas that were already sampled prior to drug 
administration were put to zero. By doing so, it was assumed that mites 
do not move across the animals’ skin. Although this does not happen in 
reality, this assumption hugely simplified the data generation process. 
In a third step, the MCR and the corresponding 95% confidence in-
tervals (95%CI) were calculated. The MCR was calculated as: MCR (%) 
= 100 x (1 - (arithmetic mean of pre-drug administration mite counts/ 
arithmetic mean of post-drug administration mite counts)). For the 95% 
CI, a previously described methodology (Levecke et al., 2015, 2018) was 
used. Based on both MCR and the corresponding 95%CI, resulting in the 
MCRT, the therapeutic efficacy of the drug was classified into normal 
and reduced. A drug was classified as normal when the lower limit of the 
95%CI did not include 90%, and as reduced when the upper limit did not 
include 90%. 
2.1.2. Parameterisation of the simulation framework at farm, animal and 
lesion level 
In order to parameterise the simulation framework for P. ovis, values 
for both the mean (μf) and the variance (σ2f) in mite counts were 
imputed at the farm level (Level 1). At the animal level (Level 2), the 
variance in mite counts across skin areas (σ2fa), the probabilities π1 to π5, 
and the variation in skin surface were imputed. At the level of the lesion 
(Level 3), the variance in mite counts within a lesion (σ2fal) was 
required. 
2.1.2.1. Parameterisation at farm level with re-analyses of field data. To 
determine the mean (μf) and variance (σ2f) of mite counts at farm level, 
the mite count data collected during a series of published acaricide drug 
efficacy trials were re-analysed. This dataset included mite counts of 154 
animals from 16 farms (7–13 animals per farm) based on 3 scrapings of 
9 cm2 per animal taken from a varying number of lesions per animal 
(1–3) or predilection locations (withers, midback or tail-base) when 
lesions were considered too small (van Mol et al., 2020). To cover a wide 
range of possible mean mite counts at farm level (μf) into the simulation, 
the 5th, 50th and the 95th percentile of the mean mite counts/9 cm2 
were determined at these 16 farms (per farm the mean mite counts at the 
individual level was averaged). For the variance in mite counts between 
individuals of the same farm (σ2f), a linear regression model was built 
with the log transformed mean mite counts at the farm level (μf) as in-
dependent variable and the log transformed variance in mean mite 
counts across individuals at the farm level (σ2f) as dependent variable. 
2.1.2.2. Parameterisation at the individual animal level with new field 
data. A new field study was designed to characterise the variance in 
mite counts within an individual animal (σ2fa), difference in mite counts 
across both lesions and healthy skin areas (probabilities π1 to π5) and the 
individual variation in skin surface of the back. In this study, 15 animals 
(≥2 years old) across three farms with confirmed psoroptic mange were 
included. In total, 27 skin scrapings (9 cm2) were collected per animal, 
of which 9 samples were taken from each of the 3 regions of the back 
(the withers, the midback and the tail base region). If lesions were 
present in a region, the samples were taken randomly within a lesion. 
When no lesions were present in a region, the samples were taken from 
predefined locations. The lesions were sketched on a silhouette and 
sampling locations were recorded (see Supplementary Fig. 1). The 
length from withers to tail-base and the width at the shoulders and tuber 
coxae was measured for all animals with a tape measure. Skin scrapings 
were transported and stored at room temperature. Within five days after 
collection of the skin scrapings, the P. ovis mites (living and unrespon-
sive intact) were counted as previously described (van Mol et al., 2020). 
Per individual animal, the mean mite counts at the sampling area (μsa) 
were averaged, which was either a lesion or healthy skin. 
For the variance in mite counts within individuals of the same farm 
(σ2fa), a linear regression model was built with the log transformed mean 
of the averaged mite counts across the lesions and healthy skin areas 
(~μfa) as independent variable and the log transformed variance in the 
averaged mite counts across the lesions and healthy skin areas (~σ2fa) as 
dependent variable. For this analysis, only animals for which μfa >
0 were included. 
To determine the probabilities π1 to π5, the averaged mite counts 
were stratified across the lesions and healthy skin areas combined based 
on their quintiles, resulting in 5 levels of mite infestation. Subsequently, 
the proportion of averaged mite counts of lesions that fell in each of 
these 5 levels of mange infestation were determined. For this analysis, 
only lesions and healthy skin sampling areas for which 9 scrapings were 
available were included. 
To impute the surface of the lesions, the mean, smallest and largest 
length from the withers to the tail base and averaged width (at the 
shoulders and tuber coxae) across the different animals was determined. 
Subsequently, these values were multiplied by each other (smallest 
length x smallest width; mean length x mean width; longest length x 
widest width), resulting in three values for total surface of the back 
(small, medium and large animals). To also allow for variation in size of 
lesions within an animal, the total surface of the back was arbitrarily 
divided into 12 equal parts, ranging from 1/12 to 12/12 of the back of an 
animal. 
2.1.2.3. Parameterisation at lesion level. To determine the variation in 
mite counts across lesions, a linear regression model was built with the 
log transformed mean mite counts in lesions and healthy sampling areas 
combined (~μfal) as independent variable and the log transformed 
variance in mean mite counts across lesions and healthy skin sampling 
areas (~σ2fal) as dependent variable. For this analysis, lesions and 
healthy skin sampling areas were only included for which 9 scrapings 
were available. 
2.1.3. Impact of number of skin scrapings on post-drug administration mite 
counts 
As a result of the skin scrapings, a fraction of the total mite popu-
lation on an animal will always be removed. This removal of mites may 
potentially hide an underlying reduced therapeutic efficacy through 
overestimation of the reduction. Since this fraction increases as more 
skin scrapings are collected per animal, it will be important to minimize 
the number of scrapings to the strict minimum. Therefore, a separate 
Fig. 1. General overview of the simulation framework for mite counts. On a given farm f (Level 1) with predetermined mean (μf), variation (σf) in mite counts and level of 
aggregation (kf), a number of animals (na) with their respective mean (μfa), variation (σfa) in mite counts and level of aggregation (kfa) were drawn (Level 2) from a negative 
binomial distribution (NBD) or Poisson distribution. Subsequently, 1000 skin areas were generated per animal and divided over their respective quintiles, each quintile rep-
resenting a different level of mite infestation. From these quintiles, nl lesions were proportionally (π1 - π5) drawn with their respective mean (μfal), variation (σfal) in mite counts 
and level of aggregation (kfal) (Level 3). Then, ns skin scrapings were sampled from these lesions with a surface equal to Sfal. Post-drug administration mite counts (MC) within 
each lesion were generated by multiplying the pre-drug administration by 1 – TDEd (= the true underlying drug efficacy of the drug d) and ns skin scrapings were sampled from 
the same lesion. The observed drug efficacy (ODE), consisting of the mite count reduction (MCR) and the 95% confidence intervals (95%CI), were calculated, resulting in the 
mite count reduction test (MCRT). Depending on the preferred definition of normal drug efficacy, MCR≥90% or MCR≥95%, efficacy was classified as either normal (lower 
limit (LL) of 95%CI was at least 90% or 95%) or reduced (upper limit (UL) of 95%CI was less than 90% or 95%). Finally, the outcome of the MCRT was compared to the true 
drug efficacy of the given mite population. 
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simulation study was performed in order to explore the impact of the 
number of skin scrapings on post-drug administration mite counts. In 
this simulation study, the first step of the aforementioned simulation 
framework was applied that was subsequently parameterized based on 
the methodology described in Section 2.1.1. For each iteration, the 
proportion of the total number of mites that were removed was 
determined. 
In this simulation, μf (the mite infestation at the farm level) was fixed 
to the 50th percentile of the mean mite counts at the 16 aforementioned 
farms, na (number of animals) to 6 and nl (number of lesions) to 1. The 
variation in surface of the lesion varied from 1/12 to 12/12 of the back. 
To also explore the individual variation in size of the animal, three 
different values in cm2 were imputed for 1/12. These absolute values for 
surface correspond with the smallest, medium and largest measured 
surface of a back on the animals (See Section 2.1.1.2.). The number of 
scrapings of 9 cm2 per lesion (ns) was set at 1, 2, 3, 6, 9, 12, 15, 18, 21, 
24, 27 and 30, resulting in 432 unique combinations (1 μf x 1 na x 1 nl x 
12 parts of the back x 3 absolute surfaces for 1/12 of a back x 12 ns). 
2.2. Application of simulation framework to explore the impact of both 
study specific and biological factors on the diagnostic performance of 
MCRT 
To gain insights in the impact of both study specific and biological 
factors on the diagnostic performance of MCRT, a final simulation study 
was performed. In this simulation study, the complete simulation 
framework was applied that was subsequently parameterized based on 
the methodology described in Section 2.1.1.). In total, the impact was 
explored of the mean mite infestation at the level of farms (μf = 5th, 50th 
and 95th percentile of the mean mite counts at the 16 aforementioned 
farms), number of animals (na = 6, 10, 15 and 20) and TDEd (= 70.00, 
72.50, 75.00, 77.50, 80.00, 81.25, 82.50, 83.75, 85.00, 86.25, 87.50, 
88.75, 90.00, 91.25, 92.50, 93.75, 95.00, 96.25, 97.50 and 98.75). For 
the number of scrapings (ns) and the surface sizes of the lesions (Sfal), 
which was based on both the proportion of the back and the individual 
size of the individual animal, our selection was based on the outcome of 
the separate simulation described in Section 2.1.2. This was done 
because it would be redundant to include combinations of ns and Sfal, 
where high proportion of the mites are already removed prior to drug 
administration. Therefore, only those combinations of ns and Sfal, were 
considered for which the proportion of mites removed was less than 10% 
in half of the iterations. A total of 627 combination fulfilled these re-
quirements, resulting in a total of 7524 unique combinations (3 μf x 4 na 
x 627 ns - Sfal) for each of the 20 values of TDEd 
For each of these 7524 combinations, the TDEd was determined for 
which a normal and reduced efficacy could be reliably detected. In case 
of a normal drug efficacy (TDEd ≥90%), this corresponded with the 
lowest possible TDEd for which type I error (α; probability of reduced 
efficacy (TDEd <90%) falsely classified as normal) and type II errors (β; 
probability of classifying normal efficacy (TDEd ≥90%) as reduced) are 
not higher than 5% and 20%, respectively. In case of a reduced drug 
efficacy (TDEd <90%), this corresponded with the highest possible TDEd 
for which α (probability of normal efficacy (TDEd ≥90%) falsely classi-
fied as reduced) and β (probability of classifying reduced efficacy (TDEd 
<90%) as normal) are not higher than 5% and 20%. A general graphical 
representation of this analysis is shown in Fig. 4, Panel A. In this 
example, the lowest possible TDEd ≥90% that can reliably be detected is 
92.5%, the highest TDEd <90% that could be detected is 83.8%. For both 
these TDEd, α and β are not higher than 5% and 20%, respectively. For 
any value TDEd between 83.8% and 92.5%, the detection of normal and 
reduced efficacy remained unreliable. This range of TDEd is referred to 
as the grey zone. 
3. Results 
3.1. Parameterisation of the simulation framework 
The parameterisation of the simulation framework is illustrated by 
Fig. 2. The mean mite counts at the farm level (μf) ranged from 4.7 to 
42.3 mites/9 cm2, with the majority within the range of 10–20 mites/9 
cm2 of skin scrapings (Fig. 2, panel A). The 5th-, 50th- and 95th-quan-
tiles of μf equalled 6.0, 15.4 and 31.3 mites/9 cm2 of skin scrapings, 
respectively. 
To estimate the variances at the different levels (farm: σ2f, animal: 
σ2fa and lesion: σ2fa), linear regression models were built with the cor-
responding mean at the different levels as independent variable (farm: 
μf, animal: μfa and lesion: μfal). The equations below represent the output 
of these models at the level of farm (Eq (1)), animal (Eq (2)) and lesion 
(Eq (3)). The graphical representation of the estimations and the cor-
responding 95% prediction intervals are provided in Panels B (farm), D 
(animal) and F (lesions) of Fig. 2. The raw data for the analysis is pro-
vided in Supplementary Info I2.  
Eq (1): log(σ2f) = 2.376 x log (μf) - 0.181 + εf ~ normal(0,0.7512)                 
Eq (2): log(σ2fa) = 1.855 x log (μfa) + 0.073 + εfa ~ normal(0,1.1232)            
Eq (3): log(σ2fal) = 1.637 x log (μfal) – 1.186 + εfal ~ normal(0,0.5452)          
Across the lesions (n = 24) and the healthy skin areas (n = 14), the 
20th, 40th, 60th and 80th percentile of the mean mite counts equalled 
0.0, 0.4, 2.3 and 13.7 mites/9 cm2, resulting in 5 levels of mite in-
festations: 0.0, 0.0–0.4, 0.4–2.3, 2.3–13.7, ≥13.7 mites/9 cm2. Across 
these levels of mite infestation, the mite counts from lesions were mainly 
found at the higher levels of infestation (Fig. 2, Panel E). Approximately 
60% of all the mite counts in lesions were classified in at least the fourth 
level of mite infestation (mean mite counts/9 cm2 ≥ 2.3), whereas for 
healthy skin areas, all values for the mite counts fell in the first three 
levels of mite infestation. For lesions, the probabilities across the five 
levels of mite infestation were 16.7% (π1), 8.3% (π2), 12.5% (π3), 58.3% 
(π4) and 4.2% (π5). The mean length was 109 cm (smallest = 85 cm and 
largest = 128 cm) and the mean width was 40 cm (smallest = 30.5 cm 
and largest = 52 cm). Subsequently, this resulted in a mean surface of 
the back of 4380 cm2 and corresponding minimum and maximum sur-
faces of 2592 cm2 and 6656 cm2. The size of 1/12th of a back across 15 
animals from 3 farms varied from 216 to 555 cm2, corresponding with 
24 and 62 skin scrapings of 9 cm2, respectively. 
3.2. Impact of number of skin scrapings on post drug administration mite 
counts 
Fig. 3 illustrates the impact of the number of skin scrapings (size of 9 
cm2) on post-drug administration mite counts. For a clear presentation 
of the data, and alignment with the selection of number of scrapings and 
the size of the lesions in the final simulation, the highest number of 
scrapings was determined that resulted in a mite reduction not 
exceeding 1%, 5% and 10% in at least half of the iterations. Overall, 
more samples can be sampled per lesion when the lesions covered more 
skin surface (1/12 vs. 12/12 and small vs. large animals) and when a less 
stringent mite reduction cut-off was applied (1% vs. 10%). When a mite 
reduction cut-off of 10% was assumed, one can take the maximum 
number (n = 30) of skin scrapings from lesions covering 5/12 of the back 
of large animals, whereas for medium sized animals this is only possible 
when lesions cover 8/12 of the back. For small animals, the highest 
number of scrapings was 27 and this was only possible when the lesion 
covered the entire back (12/12). For a 5% mite reduction cut-off, similar 
trends were observed, yet collection of 30 skin scrapings per lesion was 
only possible for large animals (from lesions covering 10/12 of the back 
onwards). For medium and small animals, the highest possible number 
of scrapings for lesions covering the entire back was 24 and 12, 
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respectively. For a 1% mite reduction cut-off, the highest possible 
number of scrapings did not exceed 6, regardless of the size of the le-
sions. Supplementary Table T2 provides the highest possible number of 
skin scrapings across the different absolute surfaces of lesions (1/12 vs. 
12/12 and small vs. large animals) that were included in the final 
simulation. 
Fig. 2. The parameterisation of a simulation framework for P. ovis mite counts. Panel A describes the distribution of mean mite counts per 9 cm2 across 16 farms, whereas the 
full vertical line represents the median, and the vertical dashed lines indicate the 5th (left of median) and the 95th percentile (right of median). Panel B illustrates the output of the 
linear regression model with the variance in mite counts at farm level (σ2f) as dependent variable and mean mite counts at farm level (μf) as independent variable. The black dots 
represent the data, the straight black line the estimated σ2f as function of μf and the red dashed lines represent the 95% prediction intervals. Panel C illustrates the distribution of 
the length and the width. The length of the individual animals is given on the horizontal axis, whereas the average width of an animal is given on the vertical axis. Panel D 
illustrates the output of the linear regression model with the variance in mite counts at animal level (σ2fa) as dependent variable and mean mite counts at animal level (μfa) as 
independent variable. The black dots represent the data, the straight black line the estimated σ2f as function of μf and the red dashed lines represent the 95% prediction intervals. 
Panel E describes the distribution of the mite counts found in lesions (black bars) and healthy skin areas (white bars) over 5 levels of mite infestation. Panel F illustrates the 
output of the linear model with the variance in mite counts at lesion level (σ2fal) as dependent variable and mean mite counts at lesion level (μfal) as independent variable. The 
black dots represent the data, the straight black line the estimated σ2f as function of μf and the red dashed lines represent the 95% prediction intervals. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the Web version of this article.) 
Fig. 3. The maximum number of skin scrapings for different surfaces of lesions and mite reduction thresholds. The maximum number of scrapings of 9 cm2 for 
different surfaces of lesions that resulted in a mite reduction not exceeding 1% (green lines), 5% (red lines) and 10% (black lines) in at least half of the iterations. The 
size of the lesions is expressed as a proportion of an animal’s back (1/12 to 12/12). The dot represents a medium sized animal (surface back = 4380 cm2), with the 
top and bottom whiskers representing a large (surface back = 6656 cm2) and small animal (surface back = 2592 cm2), respectively. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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3.3. Application of the simulation framework to explore the impact of 
both study specific and biological factors on the diagnostic performance of 
MCRT 
3.3.1. The diagnostic performance of MCRT when it is applied according to 
the existing WAAVP and EMA guidelines 
Fig. 4, Panels B, C and D illustrate the diagnostic performance of 
MCRT when it is applied according to both the WAAVP (panels B: 6 skin 
scrapings per animal, i.e. either 6 skin scrapings from 1 lesion or 1 skin 
scraping from 6 lesions and Panel C: 2 skin scrapings per animal, i.e. 
either 2 skin scrapings from 1 lesion or 1 skin scraping from 2 lesions), 
and EMA guideline (Panel D: 15 animals; 3 skin scrapings per animal 
taken from 3 lesions). Across the different panels, it was assumed that 
the mean infestation at the farm equalled 15.4 mites/9 cm2, all animals 
were of medium size (total surface of the back = 4380 cm2) and that only 
lesions covering 2/12 of the back were sampled. When applying the 
WAAVP guidelines, a reduced efficacy of 70% could not be reliably 
detected, although the type II error (β) was only slightly above 20% 
when 6 skin scrapings were collected per animal. When applying the 
EMA guidelines, MCRT was able to reliably detect reduced efficacies up 
to 72.5%. The detection of normal drug efficacy was similar between 
both guidelines, the MCRT generally being able to reliably detect normal 
drug efficacy when the TDEd was at least 95%. Only for 2 skin scrapings 
(1 scraping from 2 lesions), the TDEd for which the type II error was less 
than 20% equalled 97.5%. 
3.3.2. Guidance to optimize the diagnostic performance of the MCRT 
In Supplementary Figs. S2 and S3 the impact of the different study 
specific factors is graphically summarized (number of animals, number 
of lesions per animal, number of skin scrapings per lesion and surface of 
the lesions (proportion of the back covered and the size of the animals)) 
on the diagnostic performance of MCRT to detect reduced (TDEd <90%) 
and normal drug efficacy (TDEd ≥90%), respectively. Generally, the 
diagnostic accuracy increased (narrow grey zone) as a function of 
increasing number and size of animals, number of lesions sampled, the 
number of skin scrapings per lesion and intensity of mite infestation. For 
varying surface of sampled lesion, the diagnostic accuracy of MCRT 
remained largely unchanged. 
In Fig. 5, the different options to design a MCRT were presented in 
farms with an average mite infestation (μf = 15.4 mites/9 cm2) in 10 
medium sized animals (total surface of the back = 4380 cm2). For farms 
of this type, we determined the diagnostic accuracy of MCRT depending 
on the size of the lesions (1/12 vs. 6/12 vs. 12/12 of the animal’s back) 
and the number of skin scrapings. Based on the width of the grey zones, 
it is clear that collecting 1 sample per scraping is not recommended. 
Changing parameters that increase the number of scrapings per animal, 
as number of scrapings per lesion or number of sampled lesions narrow 
the width of the grey zone. The possible changes and resulting grey 
zones can be identified in Fig. 5. In Supplementary Info I3, the diagnostic 
performance for each of the 7524 combinations (3 levels of mite infes-
tation on farm level x 4 numbers of animals x 627 numbers and sizes of 
lesions) was summarized. To ensure oversight of the different combi-
nations, this was converted into a supporting tool that allows veteri-
narians/researchers to identify the MCRT design that best fits their 
purpose. The sliders can be used to select only the scenarios with the 
fixed parameters. For every combination with the chosen parameters, 
Fig. 4. The diagnostic performance of a mite count reduction test to detect reduced and normal drug efficacy against P. ovis across a selection of combinations. Panel A 
represents a general format of the results of the simulation of a given combination. The true underlying drug efficacy of drug d (TDEd) is given in the x-axis, with the reduced drug 
efficacy threshold (90%) represented by a vertical line. The probability (or proportion of iterations) is given in the y-axis. The green line represents the probability of classifying 
the efficacy of drug d as normal based on the mite count reduction test (MCRT), while the red line represents the probability of classifying the efficacy of drug d as reduced based 
on the MCRT. Type I (α) and type II errors (β) were set at 5% and 20% respectively. The grey area indicates the range of TDEd for which α ≥5% or β ≥20. Panel B and C 
illustrate the WAAVP guidelines (Panel B: 6 animals and 6 skin scrapings per animal; Panel C: 2 skin scrapings per animal), and Panel D the EMA guideline (15 animals and 3 
skin scrapings per animal). In each Panel, the green line depicts the probability of classifying the efficacy of drug d as normal based on the MCRT, while the red line represents the 
probability of classifying the efficacy of drug d as reduced based on the MCRT. In Panels B and C, the solid line represents multiple skin scrapings (Panel B: 6; Panel C: 2) taken 
from 1 lesion, whereas the dotted line indicates that 1 skin scraping was collected from multiple lesions (Panel B: 6; Panel C: 2). Type I (α) and type II errors (β) were set at 5% 
and 20%, respectively. The grey area indicates the range of TDEd for which α ≥5% or β ≥20%. In these Figures, it was assumed that the mean infestation at the farm equalled 
15.4 mites/9 cm2, all animals where of medium size (back=4380 cm2) and that only lesions covering 1/12 of the back where sampled. (For interpretation of the references 
to colour in this figure legend, the reader is referred to the Web version of this article.) 
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the corresponding grey zone will be given. 
4. Discussion 
Recent reports on macrocyclic lactone resistance and the likelihood 
of the development of resistance against other acaricides, highlight the 
need for monitoring the therapeutic efficacy of acaricides (Lifschitz 
et al., 2018; van Mol et al., 2020). However, the absence of 
evidence-based guidelines and the wide variation in sampling strategies 
currently being implemented make it difficult to directly compare re-
sults of different studies and to optimize the diagnostic accuracy of 
MCRT to correctly detect normal and reduced efficacy. In the present 
study, a unique simulation framework was constructed that accounts for 
the most relevant biological features of P. ovis infestations. Second, this 
framework was applied to explore the impact of both study-specific and 
biological factors on the diagnostic performance of the MCRT. The 
outcome of the simulation study provided a basis to determine the 
diagnostic performance of the MCRT when it is applied according to the 
existing WAAVP and EMA guidelines, and to make recommendations on 
how to ensure a good diagnostic performance of the MCRT while 
minimizing the number of animals and samples needed. Finally, a simple 
tool was developed that will help researchers and veterinarians to 
optimize the design of the MCRT to their own field settings. 
4.1. First description of mite distribution across farms, individual animals 
and lesions 
This is one of the first studies to give a detailed description of the 
distribution of P. ovis in naturally infested cattle between and within 
both animals and lesions. Most studies either limited the mite counts to 
100 mites per animal (Lonneux et al., 1997) or classified mite counts 
into arbitrary categories (Genchi et al., 2008; Lekimme et al., 2010; 
Lifschitz et al., 2018; Lonneux and Losson, 1992). To our knowledge, 
only Sarre et al. (2015) reported the mean, minimum and maximum 
mite counts observed in two farms, but no variance. 
The distribution of P. ovis follows a negative binomial distribution, 
when the aggregation value is positive. This means that a minority of the 
animals on a farm contain the majority of the mites. This is also observed 
in for gastrointestinal nematodes infections (Levecke et al., 2012). The 
same distribution is also observed within an animal and lesion, where a 
minority of the lesions or sampling locations within a lesion contain the 
majority of the mites. However, low mean mite counts within a farm, 
animal or lesion follow a Poisson distribution, due to the high correla-
tion between mean mite count and the variance. 
4.2. A novel and mite specific simulation framework 
A novel simulation framework for mimicking of field efficacy trials 
was described that accounts for a series of mite specific features and that 
is parameterized using field data at farm, animal and lesion level. The 
use of a simulation has the advantage to generate a lot of data in a 
relative short time and with low cost. It would be impossible to collect 
the same amount of data through actual farm visits, as the simulation 
framework generated 72,240,000 farm visits. In comparison, Belgium 
had 3089 beef cattle farms in 2017 (Danckaert et al., 2018). 
Similar work has been done with the FECRT (Levecke et al., 2012, 
2018), but the simulation framework for P. ovis differs in mite specific 
biological features and sampling methodology. The mite specific pa-
rameters were quantified through the analysis of field data. The sam-
pling methodology in P. ovis is based on the collection and counting of 
the parasite itself rather than the eggs that are dispersed by the parasite. 
A consequence is that a proportion of the parasite population is removed 
due to sampling. The framework also identified a maximum recom-
mended number of samples per given lesion surface. A 1% reduction 
cut-off resulted in a limited number of possible sampling strategies, as 
only 3 samples could be taken from a medium sized animal when more 
than half of its back is covered with lesions. Therefore, a minimum 
reduction of mite numbers through sampling should always be accepted. 
Because of the possibility of false positive detections of normal efficacy, 
the framework allowed for a maximum number of samples with a 50% 
Fig. 5. The diagnostic performance of MCRT for a farm with an average mite infestation in 10 medium sized animals. The grey zone of the different combinations is 
illustrated through the grey horizontal bar. The TDE values with a type II error <20% for the detection of normal and reduced efficacy are depicted by a white and 
black bar respectively. All combinations have a fixed mite infestation intensity (50th percentile = 15.4 mites/9 cm2) and a fixed number (n = 10) of medium sized 
(total surface back = 4380 cm2) animals. 
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probability to give a 10% reduction. 
The use of the simulation framework has possibilities beyond the 
application in this paper. For example, validation of diagnostic meth-
odologies, detection limit of mite infestation intensity in asymptomatic 
carriers or expansion of the range of the parameters affecting the MCRT. 
4.3. The simulation framework comes with its limitations 
While the simulation framework is valuable to gain insights into to 
diagnostic performance of MCRT, it can only be as good as the as-
sumptions made. Consequently, it is important that the results of the 
presented simulations are interpreted with some caution. An overview 
of all assumptions and their potential impact on the interpretation of the 
results is given in Supplementary Info I4. In the following paragraphs, 
the most important limitations are discussed. 
The parameterisation of the simulation framework was based on 
field data with given minimum and maximum values for mite infestation 
intensity, animal size, lesion size and number of lesions, and hence the 
findings should not be extrapolated to values other than those incor-
porated in the simulation study. For example, the effect of mite infes-
tation intensities outside the range of this study on the diagnostic 
performance of the MCRT was excluded from the simulation framework. 
The mite counts in the present study can be considered low or medium 
compared to other studies (Lonneux and Losson, 1992; Sarre et al., 2015; 
Lifschitz et al., 2018). However, it would be expected that the diagnostic 
performance of the MCRT on a farm will benefit from higher mite 
infestation intensity. 
Another limitation of the framework is the exclusion of dynamics in 
the parameters, such as the size of the mite populations, lesions and 
animals, which could bring additional variation in the sampling results. 
For example, it was assumed that there is no growth of the mite popu-
lation. However, there could be an increase in the population after 
treatment, due to successful reproduction of resistant individuals. This 
could result in an underestimation of the reduction. More research is 
needed to know the full impact population dynamics. Wall et al. (1999) 
have simulated population growth in sheep in a favourable environ-
ment, but no data are available for population growth of P. ovis in cattle. 
The diagnostic performance of the MCRT based on the WAAVP and 
EMA guidelines detects normal efficacy reliably, but may fail to detect 
reduced efficacy. 
In order to detect normal efficacy with sufficient power (type II error 
<20%), the underlying TDE needs to be at least 95% for both guidelines. 
In this simulation framework, the lowest possible limit of the grey zone 
for the detection of normal drug efficacy was 92.5%, and hence this 
small difference shows an acceptable performance of the guidelines for 
the detection of normal drug efficacy. 
In a best-case scenario, MCRT based on the WAAVP guidelines can 
only reliably detect resistance when the underlying TDE is 70% or less. 
Other scenarios could not detect resistance in our dataset with a type II 
error less than 20%. The EMA recommendations performed slightly 
better, but still resulted in a wide grey zone [74%–95%]. 
A difference in the methodology of the simulation framework is the 
incorporation of the 95%CI to account for the present uncertainty, while 
both guidelines only used the observed mean reduction. The 95%CI have 
been used for multiple methodologies in the FECRT. The inclusion of an 
intermediate class of acaricide susceptibility based on the 95%CI 
acknowledged the uncertainty in the FECRT (Levecke et al., 2018). This 
methodology has also been used for the MCRT in P. ovis by van Mol et al. 
(2020). 
The reliability of the detection of the therapeutic drug efficacy in-
creases with the total number of samples per farm. 
In order to reduce the type II error (increase the power) of MCRT, it is 
recommended to increase the number of total samples collected per 
farm. This can be achieved through the number of animals, the number 
of sampled lesions and the number of samples per lesion. The possibility 
to change multiple parameters opens up for a more flexible use of 
parameters. For example, if the number of animals is limited on a farm 
more samples can be taken per animal until their number is limited by 
the lesion’s size or when lesions are small on a farm, more animals can 
be included. 
The total number of skin scrapings per farm is restricted by biological 
factors and field settings. The lesion size is the limiting factor of the 
maximum number of samples taken per lesion, due to the removal of 
mites. In order to keep the costs of a drug efficacy trial within its limits it 
should be noted that the counting of the mites in the skin scrapings is a 
labour and time-consuming procedure. Thus, an increase in the total 
samples per farm will result in a higher labour cost. 
The mite infestation intensity also had an impact on the grey zone of 
the MCRT. Even though it is not always an option, pre-treatment 
screening of the mite infestation intensity of the animals and selection 
of animals with a high mean mite count is recommended. It should be 
noted that the selection of animals with larger lesions will not provide a 
higher mite infestation intensity, due to the poor correlation between 
mite counts and lesions extent (van Mol et al., 2020). The size of a lesion 
did not have a direct effect on the type I and II errors of the MCRT, but 
should not be neglected. This is because more scrapings can be collected 
from larger lesions before the reduction in mite numbers caused by the 
sampling becomes too big. Thus, including animals with larger lesions 
increases the allowed maximum number of samples per lesion. 
Even though the grey zone can be reduced through optimisation of 
the sampling parameters, it is important to note that there was always a 
grey zone around the threshold, even when the best possible scenario of 
20 large animals with 30 samples taken from each of the 12 lesions was 
executed. 
A tool to guide farmers/veterinarians in designing MCRT based on 
their operational resources and field settings.Whereas every setting for a 
MCRT is unique, it could be difficult to find the right balance between a 
sampling strategy with the highest diagnostic performance and available 
resources. Therefore, the table with all generated scenarios (Supple-
mentary Info I3) was translated into a simple supporting tool that gen-
erates the grey zones of possible sampling strategies for the fixed 
parameters of the field setting. Selection of the desired parameters with 
the sliders in the file excludes all scenarios that are not eligible within 
the study set-up. The user can then quickly identify the best combination 
of parameters for his/her setting based on the corresponding grey zone. 
Due to the presence of a grey zone for every combination and the 
limits of every field setting to alter the sampling strategies, an acceptable 
grey zone needs to be aspired. A tentative acceptable window is between 
TDE values of 80% and 95%. In the example used in Fig. 5, this means 
that combinations that result in 12 samples per animal would be 
recommended. 
The use of a mite count reduction of 90% as normal efficacy 
threshold can be a matter of debate, due to the aggressive nature of the 
disease and the rapid growth of the population (Kirkwood, 1986; Losson 
et al., 1999; Wall et al., 1999; Bridi et al., 2001; Fischer and Walton, 
2014). In order to facilitate a possible increase of the threshold, the grey 
zones with a 95% normal efficacy threshold have been determined for 
all included combinations of parameters and can be found in Supple-
mentary Info I3. 
5. Conclusion 
A novel and mite specific simulation model was developed that 
allowed to gain insights into the use of the MCRT for the detection of 
acaricide resistance in P. ovis in cattle. The current WAAVP and EMA 
guidelines performed well for the detection of normal drug efficacy, but 
poorly for reduced drug efficacy. The diagnostic performance of the 
MCRT can be improved by increasing the total number of skin scrapings 
on a farm (e.g. by increasing the number of animals, number of sampled 
lesions and number of samples per lesion). In order to help researchers 
and veterinarians to further optimize the design of the MCRT to their 
own field settings, the findings were translated into a simple calculation 
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Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi.org/10.1016/j.ijpddr.2020.09.002. 
Supplementary Fig. S1. Silhouette of a cattle back with the three regions of the back, i.e. withers, midback and tail base region. If lesions were absent in a 
region, the samples were taken from the predefined locations on the figure. This figure was also used to sketch the lesions and to record the location of the samples 
within a lesion. 
Supplementary Fig. S2. Determination of the effect of different parameters on the detection of a reduced drug efficacy. The bar charts give the distribution of 
the lower limits of the grey zone over the intervals in function of the parameter. The lower limit of the grey zone is the true underlying drug efficacy that is correctly 
classified as reduced with a power of less than 80%. The parameters observed were mite infestation intensity, the number of animals, the size of the animals, the 
size of the lesions, the number of sampled lesions and the number of samples per lesion. 
Supplementary Fig. S3. Determination of the effect of different parameters on the detection of a normal drug efficacy. The bar charts give the distribution of 
the upper limits of the grey zone over the intervals in function of the parameter. The upper limit of the grey zone is the true underlying drug efficacy that is 
correctly classified as normal with a power of less than 80%. The parameters observed were mite infestation intensity, the number of animals, the size of the 
animals, the size of the lesions, the number of sampled lesions and the number of samples per lesion. 
Supplementary Table T1. The results of the mite counts are given for each farm. Mean 
mite counts (μf) are given per sampling location per animal per farm. The variance be-
tween animals within a farm is σ2f. The aggregation value for each farm (kf) was 
calculated with kf (= μf2/(σ2f - μf)).  
Farm μf σ2f kf 
1 18.15 402.03 0.86 
2 13.70 387.10 0.50 
3 14.53 296.72 0.75 
4 27.57 722.32 1.09 
5 8.15 356.20 0.19 
6 20.33 2103.44 0.20 
7 10.53 692.65 0.16 
8 4.67 13.33 2.51 
9 17.87 1037.07 0.31 
10 21.63 2479.82 0.19 
11 16.22 379.36 0.72 
12 42.27 7196.00 0.25 
13 11.87 654.84 0.22 
14 18.75 943.17 0.38 
15 12.93 156.74 1.16 
16 6.45 54.63 0.86   
Supplementary Table T2. The maximum number of skin scrapings (9 cm2) per lesion with a 50% probability to result in 10%, 5% and 1% reduction.  
Animal size Size relative to back Lesion surface (cm2) Maximum number of samples  
10% 5% 1% 
Small 1/12 216 2 1 0  
2/12 432 3 2 0  
3/12 648 6 3 0  
4/12 864 9 3 1  
5/12 1080 9 6 1  
6/12 1296 12 6 1  
7/12 1512 15 6 1  
8/12 1728 18 9 1  
9/12 1944 21 9 2  
10/12 2160 21 12 2  
11/12 2376 24 12 2  
12/12 2592 27 12 3 
Medium 1/12 365 3 2 0  
2/12 730 6 3 0 
(continued on next page) 
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(continued ) 
Animal size Size relative to back Lesion surface (cm2) Maximum number of samples  
10% 5% 1%  
3/12 1095 12 6 1  
4/12 1460 15 6 1  
5/12 1825 18 9 2  
6/12 2190 24 12 2  
7/12 2555 27 12 3  
8/12 2920 30 15 3  
9/12 3285 30 18 3  
10/12 3650 30 18 3  
11/12 4015 30 21 3  
12/12 4380 30 24 3 
Large 1/12 555 6 3 0  
2/12 1109 12 6 1  
3/12 1664 18 9 2  
4/12 2219 24 12 2  
5/12 2773 30 15 3  
6/12 3328 30 18 3  
7/12 3883 30 21 3  
8/12 4437 30 24 3  
9/12 4992 30 27 3  
10/12 5547 30 30 6  
11/12 6101 30 30 6  
12/12 6656 30 30 6 
Note: Supplementary data associated with this article. 
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